Full text is available at the source.
Abstract
An overlap-informed umbrella review evaluates the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as adjunct therapy in type 1 diabetes mellitus.
- GLP-1RAs may serve as potential adjuncts to insulin therapy for type 1 diabetes mellitus.
- Substantial variability in primary studies complicates the interpretation of existing evidence.
- Methodological differences across studies contribute to uncertainty regarding the efficacy and safety of GLP-1RAs.
Simplified